SCHEMBL26847199

SCHEMBL26847199

CCc1cccc(CSc2[nH]c(=O)cc(-c3cccs3)c2C#N)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACMSD Q8TDX5 8/20 0.48
▸ KDM4E B2RXH2 4/20 0.46
▸ PIM1 P11309 2/20 0.46
▸ MAPT P10636 5/20 0.43
▸ NPSR1 Q6W5P4 4/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ HPGD P15428 3/20 0.43
▸ TP53 P04637 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ ADORA2A P29274 2/20 0.42
▸ ADORA1 P30542 2/20 0.42
▸ ADORA2B P29275 1/20 0.42
▸ RXFP1 Q9HBX9 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ PRNP P04156 1/20 0.41
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23850235 0.87 ACMSD (0.64) ACMSDKDM4EPIM1MAPTNPSR1
SCHEMBL20339975 0.85 ACMSD (0.64) ACMSDKDM4EPIM1ALDH1A1KMT2A
SCHEMBL26847198 0.83 KMT2A (0.45) ACMSDKDM4EPIM1ALDH1A1MEN1
SCHEMBL26847345 0.82 KDM4E (0.46) ACMSDKDM4EPIM1MAPTNPSR1
SCHEMBL24088040 0.82 ACMSD (0.44) ACMSDKDM4EPIM1MAPTNPSR1
SCHEMBL24088014 0.82 ACMSD (0.68) ACMSDKDM4EPIM1MAPTNPSR1
SCHEMBL26847362 0.82 ACMSD (0.44) ACMSDKDM4EPIM1MAPTNPSR1
SCHEMBL20351090 0.82 ACMSD (0.49) ACMSDKDM4EPIM1MAPTNPSR1
SCHEMBL24087958 0.81 ACMSD (0.46) ACMSDKDM4EPIM1MAPTNPSR1
SCHEMBL26847597 0.81 ALDH1A1 (0.56) ACMSDKDM4EMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381177-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S.R.L. (IT) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381177-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 ACMSD 1/4885KDM4E 1110/4885PIM1 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback